A Human Induced Pluripotent Stem Cell−Derived Cardiomyocyte (hiPSC-CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening

Current Protocols in Pharmacology

Volumn 71, Issue 1, 2015, Pages 11.18.1-11.18.15

  Harris, Kate ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

arrhythmia; cardiac electrophysiology; cardiotoxicity; human induced pluripotent stem cell derived cardiomyocytes; multielectrode array; preclinical

Indexed keywords

ARTICLE; CARDIAC MUSCLE CELL; CELL ASSAY; DATA ANALYSIS; ELECTRIC POTENTIAL; HEART ELECTROPHYSIOLOGY; HUMAN; INDUCED PLURIPOTENT STEM CELL; MULTIELECTRODE ARRAY ASSAY; PRIORITY JOURNAL; WAVEFORM; BIOASSAY; ELECTROPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

BIOLOGICAL ASSAY; ELECTROPHYSIOLOGY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC;

EID: 84986275837     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph1118s71     Document Type: Article

References (29)

1. Abassi, Y.A, Xi, B, Li, N, Ouyang, W, Seiler, A, Watzele, M, Kettenhofen, R, Bohlen, H, Ehlich, A, Kolossov, E, Wang, X, and Xu, X. 2012. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br. J. Pharmacol. 165:1424-1441. doi: 10.1111/j.1476-5381.2011.01623.x.
2. Anson, B.D, Kolaja, K.L, and Kamp, T.J. 2011. Opportunities for use of human iPS cells in predictive toxicology. Clin. Pharmacol. Ther. 89:754-758. doi: 10.1038/clpt.2011.9.
3. Batey, A.J. and Doe, C.P. 2002. A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs. J. Pharmacol. Toxicol. Methods 48:11-19. doi: 10.1016/S1056-8719(03)00009-1.
4. Cavero, I. and Holzgrefe, H. 2014. Comprehensive in vitro proarrhythmia assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: A visionary 21st century initiative. Expert. Opin. Drug. Saf. 13:745-758. doi: 10.1517/14740338.2014.940310.
5. Doerr, L, Thomas, U, Guinot, D.R, Bot, C.T, Stoelzle-Feix, S, Beckler, M, George, M, and Fertig, N. 2015. New easy-to-use hybrid system for extracellular potential and impedance recordings. J. Lab. Autom. 20:175-188. doi: 10.1177/2211068214562832.
6. Fujiki, A, Tani, M, Mizumaki, K, Shimono, M, and Inoue, H. 1994. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. J. Cardiovasc. Pharmacol. 23:374-378. doi: 10.1097/00005344-199423030-00003.
7. Gibson, J.K, Yue, Y, Bronson, J, Palmer, C, and Numann, R. 2014. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents. J. Pharmacol. Toxicol. Methods 70:255-267. doi: 10.1016/j.vascn.2014.09.005.
8. Guo, L, Abrams, R.M, Babiarz, J.E, Cohen, J.D, Kameoka, S, Sanders, M.J, Chiao, E, and Kolaja, K.L. 2011. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 123:281-289. doi: 10.1093/toxsci/kfr158.
9. Guo, L, Coyle, L, Abrams, R.M, Kemper, R, Chiao, E.T, and Kolaja, K.L. 2013. Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol. Sci. 136:581-594. doi: 10.1093/toxsci/kft205.
10. Halbach, M, Egert, U, Hescheler, J, and Banach, K. 2003. Estimation of action potential changes from field potential recordings in multicellular mouse cardiac myocyte cultures. Cell Physiol. Biochem. 13:271-284. doi: 10.1159/000074542.
11. Harris, K, Aylott, M, Cui, Y, Louttit, J.B, McMahon, N.C, and Sridhar, A. 2013. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 134:412-426. doi: 10.1093/toxsci/kft113.
12. Khan, J.M, Lyon, A.R, and Harding, S.E. 2013. The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening. Br. J. Pharmacol. 169:304-317. doi: 10.1111/j.1476-5381.2012.02118.x.
13. Kirsch, G.E, Obejero-Paz, C.A, and Bruening-Wright, A. 2014. Functional characterization of human stem cell−derived cardiomyocytes. Curr. Protoc. Pharmacol. 64:11.12.1-11.12.26.
14. Kuryshev, Y.A, Ficker, E, Wang, L, Hawryluk, P, Dennis, A.T, Wible, B.A, Brown, A.M, Kang, J, Chen, X.L, Sawamura, K, Reynolds, W, and Rampe, D. 2005. Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312:316-323. doi: 10.1124/jpet.104.073692.
15. Laverty, H, Benson, C, Cartwright, E, Cross, M, Garland, C, Hammond, T, Holloway, C, McMahon, N, Milligan, J, Park, B, Pirmohamed, M, Pollard, C, Radford, J, Roome, N, Sager, P, Singh, S, Suter, T, Suter, W, Trafford, A, Volders, P, Wallis, R, Weaver, R, York, M, and Valentin, J. 2011. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 163:675-693. doi: 10.1111/j.1476-5381.2011.01255.x.
16. Lawrence, C.L, Bridgland-Taylor, M.H, Pollard, C.E, Hammond, T.G, and Valentin, J.P. 2006. A rabbit Langendorff heart proarrhythmia model: Predictive value for clinical identification of Torsades de Pointes. Br. J. Pharmacol. 149:845-860. doi: 10.1038/sj.bjp.0706894.
17. Liu, T, Brown, B.S, Wu, Y, Antzelevitch, C, Kowey, P.R, and Yan, G.X. 2006. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 3:948-956. doi: 10.1016/j.hrthm.2006.04.021.
18. Ma, J, Guo, L, Fiene, S.J, Anson, B.D, Thomson, J.A, Kamp, T.J, Kolaja, K.L, Swanson, B.J, and January, C.T. 2011. High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301:H2006-H2017. doi: 10.1152/ajpheart.00694.2011.
19. Meyer, T, Boven, K.H, Gunther, E, and Fejtl, M. 2004. Micro-electrode arrays in cardiac safety pharmacology: A novel tool to study QT interval prolongation. Drug Saf. 27:763-772. doi: 10.2165/00002018-200427110-00002.
20. Navarrete, E.G, Liang, P, Lan, F, Sanchez-Freire, V, Simmons, C, Gong, T, Sharma, A, Burridge, P.W, Patlolla, B, Lee, A.S, Wu, H, Beygui, R.E, Wu, S.M, Robbins, R.C, Bers, D.M, and Wu, J.C. 2013. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 128:S3-13. doi: 10.1161/CIRCULATIONAHA.112.000570.
21. Nozaki, Y, Honda, Y, Tsujimoto, S, Watanabe, H, Kunimatsu, T, and Funabashi, H. 2014. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. Toxicol. Appl. Pharmacol. 278:72-77. doi: 10.1016/j.taap.2014.04.007.
22. Omata, T, Kasai, C, Hashimoto, M, Hombo, T, and Yamamoto, K. 2005. QT PRODACT: Comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. J. Pharmacol. Sci. 99:531-541. doi: 10.1254/jphs.QT-C12.
23. Pollard, C.E, Abi, G.N, Bridgland-Taylor, M.H, Easter, A, Hammond, T.G, and Valentin, J.P. 2010. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br. J. Pharmacol. 159:12-21. doi: 10.1111/j.1476-5381.2009.00207.x.
24. Redfern, W.S, Carlsson, L, Davis, A.S, Lynch, W.G, MacKenzie, I, Palethorpe, S, Siegl, P.K, Strang, I, Sullivan, A.T, Wallis, R, Camm, A.J, and Hammond, T.G. 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58:32-45. doi: 10.1016/S0008-6363(02)00846-5.
25. Sager, P.T, Gintant, G, Turner, J.R, Pettit, S, and Stockbridge, N. 2014. Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 167:292-300. doi: 10.1016/j.ahj.2013.11.004.
26. Scheel, O, Frech, S, Amuzescu, B, Eisfeld, J, Lin, K.H, and Knott, T. 2014. Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology. Assay Drug Dev. Technol. 12:457-469. doi: 10.1089/adt.2014.601.
27. Tanaka, T, Tohyama, S, Murata, M, Nomura, F, Kaneko, T, Chen, H, Hattori, F, Egashira, T, Seki, T, Ohno, Y, Koshimizu, U, Yuasa, S, Ogawa, S, Yamanaka, S, Yasuda, K, and Fukuda, K. 2009. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem. Biophys. Res. Commun. 385:497-502. doi: 10.1016/j.bbrc.2009.05.073.
28. Valentin, J.P, Bialecki, R, Ewart, L, Hammond, T, Leishmann, D, Lindgren, S, Martinez, V, Pollard, C, Redfern, W, and Wallis, R. 2009. A framework to assess the translation of safety pharmacology data to humans. J. Pharmacol. Toxicol. Methods 60:152-158. doi: 10.1016/j.vascn.2009.05.011.
29. Wallis, R.M. 2010. Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br. J. Pharmacol. 159:115-121. doi: 10.1111/j.1476-5381.2009.00395.x.